Three stories regarding GLP-1 agonists, imaging during PCI, and the power of sham controls in procedure trials are the topics John Mandrola, MD, covers in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. FLOW Trial Positive

Novo Nordisk Stops Ozempic Kidney Trial After Early Signs of Success https://www.medscape.com/s/viewarticle/997237

- FLOW Trial – press release https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=166327

II. STEP HFpEF

Semaglutide Win in HFpEF With Obesity Regardless of Ejection Fraction: STEP-HFpEF

https://www.medscape.com/viewarticle/997185

The GLP-1 Agonist Semaglutide in HFpEF Cleared a Low Bar

https://www.medscape.com/viewarticle/995872

- STEP HFpEF substudy

- STEP HFpEF main paper

III. GLP-1 Agonist Adverse Effects

GLP-1 Agonists Linked to Higher Risk for Rare but Serious GI Complications

https://www.medscape.com/viewarticle/997128

- GI Adverse Effects of GLP-1 Agonists https://jamanetwork.com/journals/jama/fullarticle/2810542

IV. Imaging in PCI

Intravascular Imaging in PCI: Time for a Guideline Update?

https://www.medscape.com/viewarticle/995677

- Intravascular imaging during percutaneous coronary intervention: temporal trends and clinical outcomes in the USA https://academic.oup.com/eurheartj/article/44/38/3845/7226277

- HEART Review of Studies of Intracoronary Imaging During PCI https://heart.bmj.com/content/107/9/755

V. The Power of Placebo (Sham) control

Hopeful Insights, No Overall HFpEF Gains From Splanchnic Nerve Ablation: REBALANCE-HF

https://www.medscape.com/viewarticle/997318

- Transvenous Right GSN Ablationin HFpEF https://doi.org/10.1016/j.jchf.2022.05.009

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]